Page 477 - Binder2

References

(pg 14) Rapid Novor. (n.d.). Anti-drug antibody assays with
next-generation protein sequencing. Retrieved from
https://www.rapidnovor.com/anti-drug-antibody-assays-
with-next-generation-protein-sequencing/

(pg. 44) New York State Department of Financial Services.
(2022). Case Number: 202211-155528.

(pg. 72) Colombel, J. F., Sandborn, W. J., Reinisch, W., et
al. (2010). Infliximab, azathioprine, or combination therapy
for Crohn’s disease. New England Journal of Medicine,
362(15), 1383–1395.
https://doi.org/10.1056/NEJMoa0904492

(pg. 18) Menegatti, S., Benucci, M., Quartuccio, L., et al.
(2024). Immunogenicity to therapeutic antibodies: A
clinical overview. Antibodies, 13(1), 16.
https://doi.org/10.3390/antib13010016

(pg. 22) National Institutes of Health. (n.d.). Article:
https://pmc.ncbi.nlm.nih.gov/articles/PMC11682980/

(pg. 71) Xtalks. (n.d.). Top 10 best-selling immunology
drugs by recent sales data. Retrieved from
https://xtalks.com/top-10-best-selling-immunology-drugs-
by-recent-sales-data-4025/

(pg. 88) Bio-Rad. (n.d.). Anti-adalimumab antibody
(Humira). https://www.bio-rad-antibodies.com/anti-
adalimumab-antibody-humira.html

475